LEXINGTON, Mass.--(BUSINESS WIRE)--Cubist Pharmaceuticals, Inc. (Nasdaq: CBST), announced today that it has begun dosing in the First-in-Human clinical trial with CB-182,804, a potent, bactericidal, I.V. therapy for the treatment of multi-drug resistant (MDR) Gram-negative infections. This drug candidate was identified in Cubist’s internal discovery efforts. Pre-clinical studies of CB-182,804 demonstrated safety and efficacy in animal models with important Gram-negative pathogens such as Escherichia coli, Acinetobacter, Pseudomonas and Klebsiella. The IND for CB-182,804 was submitted to the FDA in December 2008.
